Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15397455 | 0.91 | AGTR2 (0.31) | MEN1KMT2A | |
| SCHEMBL15397447 | 0.83 | CHEK2 (0.33) | MEN1KMT2A | |
| SCHEMBL12934513 | 0.81 | P2RX3 (0.38) | — | |
| SCHEMBL1072609 | 0.79 | CHEK2 (0.42) | CNR2MEN1KMT2A | |
| SCHEMBL12963617 | 0.78 | KDM4E (0.30) | MEN1KMT2A | |
| SCHEMBL20309994 | 0.76 | ADORA3 (0.41) | MEN1KMT2A | |
| SCHEMBL1070739 | 0.75 | KDM4E (0.33) | — | |
| SCHEMBL1260182 | 0.75 | TDP1 (0.44) | MEN1KMT2A | |
| SCHEMBL16106959 | 0.74 | HTR3E (0.36) | MEN1KMT2A | |
| SCHEMBL3501451 | 0.71 | PDE4B (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | RRP1B, ZC3HAV1, RNASE1 | PTGER4 3551/4885CNR2 3721/4885MEN1 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.